HeartSciences Inc. — Form 8-K Summary
Event date: October 6, 2026. This is a current report about a regulatory milestone, not a periodic financial report; it does not provide financial results for a reporting period.
Business context
HeartSciences announced that the U.S. FDA granted 510(k) clearance (K260005) for its MyoVista wavECG device as a 12-lead resting electrocardiograph. The announcement was furnished under Item 7.01, with a press release included as Exhibit 99.1.
HeartSciences also disclosed that it filed an amended preliminary proxy statement on October 6, 2026, regarding its proposed business combination with Fortitude Mining Holdings, Inc. and related entities. The parties entered into the merger agreement on June 23, 2026.
Financial information
The 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no comparison with a prior period.
Outlook, risks, and other disclosures
The filing does not provide financial guidance or quantify the commercial or financial impact of the FDA clearance. Completion of the proposed transaction remains subject to conditions, including HeartSciences shareholder approval, and may be delayed or may not occur. Disclosed risks include market and macroeconomic conditions, integration and newly public-company risks, Fortitude’s exposure to volatile Zcash and other cryptocurrencies, and legal, commercial, regulatory, and technical uncertainty related to digital assets.
The filing states that Fortitude ordinarily sells or otherwise monetizes the digital assets it mines, including ZEC, and that Fortitude and affiliates, including DCG, may sell, pledge, or otherwise monetize digital-asset holdings to fund expenses and investments, hedge exposures, or realize gains. The transaction materials and related communications are not an offer or solicitation. The information in Item 7.01 is furnished, not filed for purposes of Exchange Act Section 18.
Important facts for investors to verify
- Review the FDA clearance and the complete October 6 press release for the clearance’s scope, conditions, and any information on commercialization.
- Read the amended preliminary proxy statement and any subsequent definitive proxy materials for transaction terms, shareholder voting requirements, timing, and participant interests.
- Consult HeartSciences’ latest Form 10-K and Form 10-Q for financial condition and risks; this 8-K contains no financial statements or metrics.
- Assess the disclosed transaction risks, including closing conditions and Fortitude’s cryptocurrency-related exposures.